化学
体内
组蛋白脱乙酰基酶
异羟肟酸
癌症研究
连接器
肺癌
效力
合理设计
HDAC6型
细胞
组蛋白脱乙酰酶抑制剂
细胞毒性
铅化合物
药理学
HDAC1型
癌细胞
全景望远镜
癌症
细胞培养
HDAC11型
细胞生长
结构-活动关系
体外
肺癌的治疗
作者
Xinyu Yang,Xin Li,Rui Huang,Yanting Zhou,Hai Li,Pan Yao,Yue Hu,Yuhang Liu,Changning Wang,Ping Bai
标识
DOI:10.1021/acs.jmedchem.6c01054
摘要
Targeting histone deacetylase 11 (HDAC11) represents a promising therapeutic strategy, yet developing selective inhibitors for solid tumors remains a formidable challenge. Herein, we describe the rational lead optimization of a novel series of indole-based hydroxamic acids. Guided by our previous lead PB94, a systematic, multiparameter optimization of the core, linker, and cap regions was conducted to specifically target HDAC11. This campaign yielded compound YP200, which incorporates a precisely positioned secondary amine linker and an adamantane surface-recognition cap. YP200 exhibited exceptional HDAC11 inhibitory potency (IC50 = 0.058 ± 0.01 μM) and good selectivity (>103-fold) over other HDACs. Furthermore, YP200 demonstrated good in vivo anti-tumor efficacy in a non-small cell lung cancer (NSCLC) patient-derived xenograft model. These findings validate YP200 as a promising HDAC11-targeted therapeutic candidate, significantly expanding the therapeutic arsenal for solid tumors.
科研通智能强力驱动
Strongly Powered by AbleSci AI